Incidence and Characteristics of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplant Recipients: a Retrospective Cohort Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2015 Dec 31

PMID 26715563

Citations 30

Authors

Nicole Harrison

Margit Mitterbauer

Selma Tobudic

Peter Kalhs

Werner Rabitsch

Hildegard Greinix

Heinz Burgmann

Birgit Willinger

Elisabeth Presterl

Christina Forstner

Affiliations

Soon will be listed here.

Abstract

Background: Allogeneic hematopoietic stem cell transplant (HSCT) recipients experience an increased risk for invasive fungal diseases (IFDs).

Methods: This retrospective cohort study at the Medical University of Vienna aspired to assess the incidence, characteristics and the outcome of IFDs as well as the associated risk factors in a setting where only 43 % of patients were given systemic antifungal prophylaxis during aplasia. IFDs were classified as probable or proven according to the EORTC/MSG consensus group. All adult patients (n = 242) receiving an allogeneic HSCT at the University Hospital of Vienna from January 2009 to December 2013 were enrolled.

Results: The primary outcome of this study was the one-year incidence for IFDs after HSCT, which was 10.3 % (25/242). Overall 28 patients experienced an IFD - 20 probable and 8 proven - with invasive aspergillosis being the predominant IFD (n = 18), followed by invasive candidiasis (n = 7) and pneumocystis pneumonia (n = 3). Patients with an IFD were more likely to be admitted to an intensive care unit (64 % versus 12 %, p < 0.0001) and had a significantly higher mortality in the first year after HSCT (48 % versus 25 %, p = 0.02). Multivariate regression analysis revealed that intensified immunosuppressive therapy (high-dose cortisone and basiliximab or etanercept) because of severe graft-versus-host disease (adjusted odds ratio (AOR) 3.6, p = 0.01) and transplant-associated microangiopathy (AOR 3.7, p = 0.04) were associated with an increased risk for IFD, while antifungal prophylaxis given during aplasia and post-engraftment was associated with a decreased risk (AOR 0.3, p = 0.02).

Conclusions: We documented a one-year incidence for IFDs of 10.3 % and no selection of rare pathogens at a centre with moderate use of antifungal prophylaxis. Intensified immunosuppressive therapy and transplant-associated microangiopathy were significant risk factors for IFDs.

Citing Articles

Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review.

Gow-Lee V, Abu Saleh O, Harris C, Gile J, Akhiyat N, Chesdachai S Pathogens. 2024; 13(10).

PMID: 39452757 PMC: 11510498. DOI: 10.3390/pathogens13100886.

Invasive Fungal Infection in Hematopoietic Stem Cell Transplant Recipient from an Indian Oncology Setting.

Ghafur A, Das B, Raja T, Easow J, Kartikeyan R, Easow B South Asian J Cancer. 2024; 13(3):207-214.

PMID: 39410986 PMC: 11473135. DOI: 10.1055/s-0043-57044.

Current status and new experimental diagnostic methods of invasive fungal infections after hematopoietic stem cell transplantation.

Tang Z, Wang H, Liu Y, Wang C, Li X, Yang Q Arch Microbiol. 2024; 206(5):237.

PMID: 38678508 DOI: 10.1007/s00203-024-03905-9.

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies.

Mori G, Diotallevi S, Farina F, Lolatto R, Galli L, Chiurlo M Microorganisms. 2024; 12(1).

PMID: 38257945 PMC: 10818361. DOI: 10.3390/microorganisms12010117.

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.

Gavriilaki E, Dolgyras P, Dimou-Mpesikli S, Poulopoulou A, Evangelidis P, Evangelidis N Cancers (Basel). 2023; 15(13).

PMID: 37444639 PMC: 10341183. DOI: 10.3390/cancers15133529.

References

Ullmann A, Lipton J, Vesole D, Chandrasekar P, Langston A, Tarantolo S . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356(4):335-47. DOI: 10.1056/NEJMoa061098. View

De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group.... Clin Infect Dis. 2008; 46(12):1813-21. PMC: 2671227. DOI: 10.1086/588660. View

Bochud P, Chien J, Marr K, Leisenring W, Upton A, Janer M . Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008; 359(17):1766-77. PMC: 2656610. DOI: 10.1056/NEJMoa0802629. View

Maertens J, Marchetti O, Herbrecht R, Cornely O, Fluckiger U, Frere P . European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2010; 46(5):709-18. DOI: 10.1038/bmt.2010.175. View

Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J . Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009; 48(3):265-73. DOI: 10.1086/595846. View

Mikulska M, Raiola A, Bruno B, Furfaro E, Van Lint M, Bregante S . Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009; 44(6):361-70. DOI: 10.1038/bmt.2009.39. View

Gratwohl A . The EBMT risk score. Bone Marrow Transplant. 2011; 47(6):749-56. DOI: 10.1038/bmt.2011.110. View

Guarascio A, Slain D . Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. Pharmacotherapy. 2015; 35(2):208-19. DOI: 10.1002/phar.1533. View

Omer A, Ziakas P, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee S . Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013; 19(8):1190-6. DOI: 10.1016/j.bbmt.2013.05.018. View

10.

Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D . Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational.... J Antimicrob Chemother. 2012; 67(9):2268-73. DOI: 10.1093/jac/dks189. View

11.

Slavin M, Osborne B, Adams R, Levenstein M, Schoch H, Feldman A . Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis. 1995; 171(6):1545-52. DOI: 10.1093/infdis/171.6.1545. View

12.

Fan L, Lu H, Cheng K, Li H, Xu J . Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One. 2013; 8(9):e73099. PMC: 3762835. DOI: 10.1371/journal.pone.0073099. View

13.

Kojouri K, George J . Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol. 2007; 19(2):148-54. DOI: 10.1097/CCO.0b013e3280148a2f. View

14.

Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A . Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009; 44(8):457-62. DOI: 10.1038/bmt.2009.255. View

15.

Fukuda T, Boeckh M, Carter R, Sandmaier B, Maris M, Maloney D . Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003; 102(3):827-33. DOI: 10.1182/blood-2003-02-0456. View

16.

Goodman J, Winston D, Greenfield R, Chandrasekar P, Fox B, Kaizer H . A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992; 326(13):845-51. DOI: 10.1056/NEJM199203263261301. View

17.

Maschmeyer G, Beinert T, Buchheidt D, Cornely O, Einsele H, Heinz W . Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer. 2009; 45(14):2462-72. DOI: 10.1016/j.ejca.2009.05.001. View

18.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

19.

Sun Y, Xu L, Liu D, Zhang X, Han W, Wang Y . Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation. Clin Microbiol Infect. 2013; 19(11):1029-34. DOI: 10.1111/1469-0691.12120. View

20.

Larsen H, Masur H, Kovacs J, Gill V, Silcott V, Kogulan P . Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol. 2002; 40(2):490-4. PMC: 153364. DOI: 10.1128/JCM.40.2.490-494.2002. View